REGN : Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets open in 7 hrs 1 mins

Regeneron Pharmaceuticals, Inc. (REGN)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
365.02-4.12 (-1.12%)
At close: 4:00PM EDT
People also watch
ALXNBIIBCELGVRTXBMRN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close369.14
Open369.19
Bid361.50 x 100
Ask370.90 x 100
Day's Range364.44 - 370.58
52 Week Range325.35 - 452.96
Volume632,518
Avg. Volume938,065
Market Cap38.52B
Beta1.58
PE Ratio (TTM)47.41
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can
    Investor's Business Daily12 hours ago

    Regeneron, Sanofi Look To Crush Amgen, And Rivals Say They Can

    Regeneron expects to top Amgen's recent heart-drug study in a team-up with Sanofi.

  • Financial Timesyesterday

    [$$] DNA decoding initiative to involve 500,000 middle-aged Britons

    Half a million middle-aged Britons will have their DNA decoded in a £120m collaboration between the public sector research facility UK Biobank and two pharmaceutical companies, GlaxoSmithKline and Regeneron. ...

  • Reutersyesterday

    GSK and Regeneron to mine gene data from 500,000 Britons

    Britain's GlaxoSmithKline and U.S.-based Regeneron Pharmaceuticals are embarking on a joint project with UK Biobank, the world's most detailed biomedical database, to hunt for new clues linking genes and disease. By analysing genetic variations and health in 500,000 middle-aged and older Britons, the partners said on Thursday they hoped to identify promising leads for new medicines. The aim is to analyse DNA from an initial 50,000 samples by the end of 2017, using Regeneron's large gene sequencing centre in New York.